NCT06328738 2025-11-19ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast CancerEnliven TherapeuticsPhase 1 Active not recruiting275 enrolled
NCT05824975 2024-11-25A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)GI Innovation, Inc.Phase 1/2 Recruiting358 enrolled